Crossmark

The Impact of Switching to a Second Antifibrotic in Patients With Idiopathic Pulmonary Fibrosis: A Retrospective Multicentre Study From the EMPIRE Registry

Crossref DOI link: https://doi.org/10.1016/j.arbres.2023.12.002

Published Print: 2024-02

Update policy: https://doi.org/10.1016/elsevier_cm_policy

Authors

Gregor, Jakub

Adir, Yochai

Šterclová, Martina

Mogulkoc, Nesrin

Kramer, Mordechai R.

Doubková, Martina

Plačková, Martina

Müller, Veronika

Studnicka, Michael

Žurková, Monika

Lacina, Ladislav

Lewandowska, Katarzyna

Bartoš, Vladimír

Ovesná, Petra

Májek, Ondřej

Koziar Vašáková, Martina
Funding

Funding for this research was provided by:

F. Hoffmann-La Roche

Boehringer Ingelheim

Roche
License Information

Text and Data Mining valid from 2024-02-01

Text and Data Mining valid from 2024-02-01
More Information

This article is maintained by: Elsevier

Article Title: The Impact of Switching to a Second Antifibrotic in Patients With Idiopathic Pulmonary Fibrosis: A Retrospective Multicentre Study From the EMPIRE Registry

Journal Title: Archivos de Bronconeumología

CrossRef DOI link to publisher maintained version: https://doi.org/10.1016/j.arbres.2023.12.002

Content Type: article

Copyright: © 2023 SEPAR. Published by Elsevier España, S.L.U. All rights reserved.

Document is current

Any future updates will be listed below